Novo Nordisk A/S $NVO Stake Raised by Banco Bilbao Vizcaya Argentaria S.A.

Key Points

• Banco Bilbao Vizcaya Argentaria S.A. boosted its holding in Novo Nordisk by 256.8% in Q3 to 357,521 shares, increasing its position to about $19.5 million.
• Novo Nordisk beat quarterly estimates with $1.01 EPS versus $0.90 expected and $12.43 billion in revenue, and the company announced a $1.2751 dividend payable April 8 (ex-dividend March 30).
• Regulatory and legal risks are mounting after an FDA warning about unreported semaglutide adverse events and an investor class‑action/investigation, which along with analyst downgrades has pressured the stock.

Banco Bilbao Vizcaya Argentaria S.A. lifted its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 256.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 357,521 shares of the company's stock after buying an additional 257,306 shares during the period. Banco Bilbao Vizcaya Argentaria S.A.'s holdings in Novo Nordisk A/S were worth $19,500,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in NVO. Martin Capital Partners LLC increased its stake in Novo Nordisk A/S by 53.8% during the 3rd quarter. Martin Capital Partners LLC now owns 117,577 shares of the company's stock valued at $6,524,000 after buying an additional 41,129 shares during the period. Smith Chas P & Associates PA Cpas lifted its stake in shares of Novo Nordisk A/S by 105.3% in the 3rd quarter. Smith Chas P & Associates PA Cpas now owns 405,425 shares of the company's stock worth $22,497,000 after acquiring an additional 207,959 shares during the period. Clifford Swan Investment Counsel LLC lifted its stake in shares of Novo Nordisk A/S by 13.7% in the 3rd quarter. Clifford Swan Investment Counsel LLC now owns 311,168 shares of the company's stock worth $17,267,000 after acquiring an additional 37,453 shares during the period. Markel Group Inc. boosted its holdings in shares of Novo Nordisk A/S by 4.9% in the third quarter. Markel Group Inc. now owns 2,368,649 shares of the company's stock valued at $131,436,000 after acquiring an additional 110,061 shares in the last quarter. Finally, Cantor Fitzgerald Investment Advisors L.P. bought a new position in shares of Novo Nordisk A/S in the third quarter valued at approximately $1,294,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Down 0.1%

NVO stock opened at $37.99 on Monday. The firm has a market cap of $169.61 billion, a PE ratio of 10.95 and a beta of 0.74. Novo Nordisk A/S has a 12 month low of $35.85 and a 12 month high of $82.57. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. The firm has a 50 day simple moving average of $50.14 and a 200 day simple moving average of $51.73.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The firm had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. Equities research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The business also recently announced a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be issued a $1.2751 dividend. This represents a dividend yield of 541.0%. The ex-dividend date is Monday, March 30th. Novo Nordisk A/S's payout ratio is presently 23.63%.

Analyst Ratings Changes

Several brokerages recently commented on NVO. BMO Capital Markets reissued a "market perform" rating on shares of Novo Nordisk A/S in a report on Thursday, February 5th. Citigroup started coverage on Novo Nordisk A/S in a research note on Tuesday, January 27th. They set a "neutral" rating for the company. Morgan Stanley upgraded Novo Nordisk A/S from an "underweight" rating to an "equal weight" rating and set a $40.00 price target on the stock in a research report on Tuesday, March 3rd. The Goldman Sachs Group reissued a "neutral" rating and issued a $41.00 price objective (down from $63.00) on shares of Novo Nordisk A/S in a research note on Monday, March 2nd. Finally, CICC Research began coverage on Novo Nordisk A/S in a report on Friday, January 9th. They issued an "outperform" rating and a $73.50 price objective for the company. Four equities research analysts have rated the stock with a Buy rating and nineteen have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $49.93.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo’s deal with telehealth/retail player Hims & Hers could broaden channels for GLP‑1 distribution and shift competitive dynamics in the obesity market; Hims shares have surged on the tie-up. Hims shares set for best week on record after new Novo Nordisk deal
• Positive Sentiment: Novo’s partnership with the WHO Foundation to support cardio‑renal‑metabolic programs expands its public‑health footprint and may support long‑term access and reputation in emerging markets. Novo Nordisk WHO Partnership Links Global Health Push With Valuation Story
• Neutral Sentiment: Zacks moved NVO from “strong sell” to “hold,” which slightly reduces near‑term sell‑side pressure but is not a bullish upgrade. Zacks.com
• Neutral Sentiment: Broader health‑care weakness today (NYSE Health Care Index decline) is adding to headline pressure across large pharma names, including NVO. Sector Update: Health Care Stocks Retreat Late Afternoon
• Negative Sentiment: The FDA issued a warning to Novo Nordisk about unreported semaglutide adverse events — the clearest near‑term catalyst for the share decline as it raises risks of inspections, disclosures, labeling changes, prescribing impacts and regulatory enforcement. FDA issues warning to Novo Nordisk on unreported semaglutide safety events
• Negative Sentiment: An investor class‑action/investigation notice (Pomerantz) has been announced, increasing legal risk and potential future claims tied to the disclosure of safety events. Pomerantz investor alert
• Negative Sentiment: Analyst downgrades and negative press—plus reporting that Novo Holdings’ assets shrank after the stock slump—are reinforcing selling momentum and investor concern about valuation and control‑group exposure. Novo Nordisk stock slump hits value of controlling shareholder

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.